Barclays upgraded Aveanna (AVAH) to Overweight from Equal Weight with a price target of $9.50, up from $5.50. The company reported a “thesis changing quarter” that erased concerns over regulation, the analyst tells investors in a research note. The firm says Aveanna showed “positive differentiation” within the Medicaid landscape, prompting materially higher earnings estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH:
- Aveanna Healthcare’s Earnings Call Highlights Growth and Optimism
- Aveanna price target raised to $6.75 from $5 at UBS
- Aveanna upgraded to Outperform from Market Perform at Raymond James
- Aveanna Healthcare Highlights Strong Financial Performance
- Aveanna Healthcare Reports Strong Q2 Growth and Raises 2025 Outlook